Trulicity (dulaglutide) and Mounjaro (tirzepatide) are prescribed to help manage blood sugar in people with type 2 diabetes. Trulicity also has other uses. Both drugs come as an injection that you ...

Trulicity helps lower blood sugar in adults and children ages 10 years and older with type 2 diabetes. It also may reduce major heart risks in adults with type 2 diabetes who have or are at risk for ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

The labeling for Trulicity (dulaglutide; Eli Lilly) has been updated to include use in combination with basal insulin for adults with type 2 diabetes, following approval from the Food and Drug ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that help manage blood sugar levels in adults with type 2 diabetes. Though they work in slightly different ways, they ...

In a clinical trial, the medication, whose generic name is dulaglutide, also reduced the risk for kidney problems by 15 percent. A drug typically prescribed to people with type 2 diabetes and heart ...

Trulicity (dulaglutide) and Ozempic (semaglutide) are medications classified as glucagon-like peptide 1 (GLP-1) agonists used ...

- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...

News 8 On Your Side is investigating a critical drug shortage frustrating diabetics who need the medicine.Investigator Susan Shapiro looked into the shortage and what the drug maker had to say about ...